Table 1.

Patient characteristics

No. of patientsn = 54
Gender
    Male10 (18.5%)
    Female44 (81.5%)
EGFR TKI treatment
    Gefitinib17 (31.4%)
    Erlotinib33 (61.1%)
    None4 (7.5%)
Response to prior EGFR TKI treatment
    Partial response28 (56%)
    Stable disease14 (28%)
    Progressive disease8 (16%)
    Not treated4 (7.5%)
Tumor EGFR mutation
    Exon 19 deletion20 (37.0%)
    L858R7 (12.9%)
    L861Q1 (1.9%)
    Exon 20 insertion2 (3.7%)
    Wild type13 (24.1%)
    Unknown11 (20.4%)